Abstract
Anti-tumor necrosis factor alpha (anti-TNF-α) is used in the treatment of rheumatic diseases not responsive to first-line regimens. Data on the safety of anti-TNF-α in HIV-infected patients are scarce and conflicting. We describe a case of septic shock and multiorgan failure that occurred after etanercept initiation and influenza vaccination in an HIV-infected woman with rheumatoid arthritis.
MeSH terms
-
Antiretroviral Therapy, Highly Active
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Rheumatoid / complications
-
Arthritis, Rheumatoid / drug therapy*
-
Etanercept
-
Female
-
HIV Infections / complications*
-
HIV Infections / drug therapy
-
Humans
-
Immunoglobulin G / adverse effects*
-
Immunoglobulin G / therapeutic use
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use
-
Influenza Vaccines / administration & dosage
-
Influenza Vaccines / adverse effects*
-
Influenza Vaccines / immunology
-
Middle Aged
-
Multiple Organ Failure / etiology
-
Receptors, Tumor Necrosis Factor / therapeutic use
-
Shock, Septic / etiology*
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Vaccination
Substances
-
Antirheumatic Agents
-
Immunoglobulin G
-
Immunosuppressive Agents
-
Influenza Vaccines
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Etanercept